scholarly journals A randomized-controlled trial of treatment for self-stigma among persons diagnosed with schizophrenia-spectrum disorders

2019 ◽  
Vol 54 (11) ◽  
pp. 1363-1378 ◽  
Author(s):  
Philip T. Yanos ◽  
Paul H. Lysaker ◽  
Steven M. Silverstein ◽  
Beth Vayshenker ◽  
Lauren Gonzales ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Schizophrenia Spectrum Disorders ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals The Effects of Metacognition-Oriented Social Skills Training on Psychosocial Outcome in Schizophrenia-Spectrum Disorders: A Randomized Controlled Trial

2017 ◽  
Vol 44 (6) ◽  
pp. 1235-1244 ◽  
Author(s):  
Felix Inchausti ◽  
Nancy V García-Poveda ◽  
Alejandro Ballesteros-Prados ◽  
Javier Ortuño-Sierra ◽  
Sergio Sánchez-Reales ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Social Skills ◽  
Social Skills Training ◽  
Controlled Trial ◽  
Skills Training ◽  
Psychosocial Outcome ◽  
Schizophrenia Spectrum Disorders ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia

2017 ◽  
Vol 47 (12) ◽  
pp. 2081-2096 ◽  
Author(s):  
W. T. Chien ◽  
D. Bressington ◽  
A. Yip ◽  
T. Karatzias
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Community Treatment ◽  
Schizophrenia Spectrum Disorders ◽  
Treatment As Usual ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Significant Difference ◽  
Spectrum Disorders

BackgroundWe aimed to test a mindfulness-based psychoeducation group (MBPEG), v. a conventional psychoeducation group (CPEG) v. treatment as usual (TAU), in patients with schizophrenia-spectrum disorders over a 24-month follow-up.MethodThis single-blind, multi-site, pragmatic randomized controlled trial was conducted in six community treatment facilities across three countries (Hong Kong, mainland China and Taiwan). Patients were randomly allocated to one of the treatment conditions, and underwent 6 months of treatment. The primary outcomes were changes in duration of re-hospitalizations and mental state (Positive and Negative Syndrome Scale; PANSS) between baseline and 1 week, and 6, 12 and 18 months post-treatment.ResultsA total of 300 patients in each country were assessed for eligibility between October 2013 and 30 April 2014, 38 patients per country (n = 342) were assigned to each treatment group and included in the intention-to-treat analysis. There was a significant difference in the length of re-hospitalizations between the three groups over 24 months (F2,330 = 5.23, p = 0.005), with MBPEG participants having a shorter mean duration of re-hospitalizations than those in the other groups. The MBPEG and CPEG participants had significant differential changes in proportional odds ratios of complete remission (all individual PANSS items <3) over the 24-month follow-up (37 and 26%, respectively), as opposed to only 7.2% of the TAU group (χ2 = 8.9 and 8.0, p = 0.001 and 0.003, relative risk = 3.5 and 3.1, 95% confidence interval 2.0–7.2 and 1.6–6.3).ConclusionsCompared with TAU and CPEG, MBPEG improves remission and hospitalization rates of people with schizophrenia spectrum disorders over 24 months.

Sign in / Sign up

Export Citation Format

Share Document